RecruitingExpanded accessNCT04400591 ↗Expanded Access Protocol (EAP) For Subjects Receiving Lisocabtagene Maraleucel That Is Nonconforming For Commercial ReleaseGaurav VarmaPIInterventionBiological: Nonconforming Lisocabtagene MaraleucelDatesStarted Nov 2021SponsorJuno Therapeutics, Inc.Lymphoma, Large B-Cell, Diffuse
RecruitingExpanded accessNCT04771078 ↗Expanded Access Protocol (EAP) for Patients Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial ReleaseRoger N PearsePIInterventionBiological: Nonconforming idecabtagene vicleucelDatesStarted Sep 2021SponsorCelgene CorporationMultiple Myeloma
RecruitingExpanded accessNCT05398640 ↗Expanded Access Program of AMTAGVI That is Out of Specification for Commercial ReleaseBarbara MaPIInterventionBiological: OOS AMTAGVIDatesStarted Nov 2025SponsorIovance Biotherapeutics, IncUnresectable MelanomaMetastatic Melanoma
RecruitingExpanded accessNCT05776134 ↗Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene AutoleucelGaurav VarmaPIInterventionBiological: Brexucabtagene AutoleucelDatesStarted Aug 2024SponsorKite Pharma, Inc.Mantle Cell LymphomaAcute Lymphoblastic Leukemia
RecruitingExpanded accessNCT06799221 ↗Expanded Access Program (EAP) for Obecabtagene Autoleucel (Obe-cel) Out-of-specification (OOS) in Adult Patients With Acute Lymphoblastic LeukemiaGaurav VarmaPIInterventionBiological: Out-of-specification obecabtagene autoleucelDatesStarted Jun 2026SponsorAutolus INCLymphoblastic Leukemia, Acute, AdultB Cell ALL